OBJECTIVE: To evaluate the racial differences in the efficacy and safety of @entity2780 in @entity1 with recent-onset (<2 weeks) @entity955 and @entity956 . METHODS: This study included 58 consecutive @entity1 with recent-onset @entity955 (n = 34) and @entity956 (n = 24). The mean age was 65.7 +/- 14.6 years (range, 37-86 years), 47% were @entity1 (n = 27) and 34% (n = 20) were African Americans. The duration of @entity943 ranged from 3 hours to 2 weeks. All @entity1 had echocardiography, were on therapeutic anticoagulation, had a fairly well controlled ventricular rate, normal QTc interval on 12-lead electrocardiography, and normal serum electrolytes. @entity2780 was administered as an intravenous infusion with a maximal dose of 2 mg. RESULTS: The overall conversion rate to sinus rhythm was 66% (n = 38), with 62% (n = 21) with @entity955 and 71% (n = 17) of @entity956 . Most conversions (84%) occurred within 45 minutes of @entity2780 infusion. The mean time to @entity943 conversion was 37.4 +/- 59.8 minutes. Race had a significant impact on efficacy, with increased conversions seen in African Americans (P = 0.004) and increased nonconversion seen in whites (P = 0.02). Successful conversion was not affected by the left atrial size or the presence of @entity340 , @entity101 , @entity712 , @entity301 , and @entity6 . QTc intervals were prolonged after drug administration, with a mean change of 24.6 milliseconds for all @entity1 . The @entity1162 after drug administration was greater in African Americans than in whites (27.4 vs. 23.3 milliseconds). @entity1166 occurred in 4 @entity1 (3 African Americans) and was treated with intravenous @entity2399 and electrical cardioversion. CONCLUSION: @entity2780 used for pharmacological cardioversion of @entity955 and @entity956 is more effective in African Americans but carries a higher risk of @entity1166 .

@entity2780 for pharmacological cardioversion of XXXX and flutter: impact of race on efficacy and safety.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease'] @entity1166 :: ('MESH:D016171', 'Disease') :: ['torsade de pointes', 'Torsade de pointes'] @entity2399 :: ('MESH:D008278', 'Chemical') :: ['magnesium sulfate'] @entity2780 :: ('MESH:C067192', 'Chemical') :: ['ibutilide', 'Ibutilide'] @entity956 :: ('MESH:D001282', 'Disease') :: ['atrial flutter'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity1162 :: ('MESH:D008133', 'Disease') :: ['QTc prolongation'] @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular heart disease'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmia']
@entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']
